NFKB1 and colitis: In fact, glucosamine improved colitis symptoms in DSS-treated mice by preventing intestinal epithelial cell activation and tight junction proteins expression decrease, with a parallel decrease in the nuclear factor-kappa B (NF-kB) activity and reduced TNF-α and IL-1β release [11,12].